At the 2014 World Drug Safety Congress Americas Susan Duke, GSK, gave a presentation on “Implementing benefit-risk thinking and quantification into the culture and processes of a large pharmaceutical company.”
Download and learn:
- Benefit-Risk thinking and quantitative evaluation at GSK
- How it began
- Where we are now
- Keeping it simple (unless it’s complex)
- What are the right questions?
- Where is our industry as a whole on quantitative Benefit-Risk evaluation?
Found this interesting? Join us in 2015 for the 7th annual World Drug Safety Congress Americas conference. The conference will address improving patient safety strategies, new technology applications in drug safety and will offer the most innovative and freshest case studies on current drug safety projects.